The R&D 15: How pharma’s top companies spent, won and lost on drug researchnews2026-04-30T11:15:51+00:00April 30th, 2026|Endpoints News|
China dominates big licensing deals as M&A starts 2026 with a bangnews2026-04-15T13:00:51+00:00April 15th, 2026|Endpoints News|
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-onsnews2026-01-20T13:00:25+00:00January 20th, 2026|Endpoints News|
Endpoints 100 survey 2025: Biotech CEOs are feeling more upbeatnews2025-12-11T12:00:03+00:00December 11th, 2025|Endpoints News|
Which big pharma had the busiest M&A team? Q3 biopharma deal analysisnews2025-10-15T11:00:20+00:00October 15th, 2025|Endpoints News|
Biopharma dealmaking trends: Q3 shows an upticknews2025-10-13T11:00:59+00:00October 13th, 2025|Endpoints News|
Keeping it simple: Chen Yu steers into round three with $1.3B biotech fundnews2025-10-06T12:00:53+00:00October 6th, 2025|Endpoints News|
Virtual team of researchers, advocates try to break 40-year logjam in osteosarcomanews2025-09-25T15:15:19+00:00September 25th, 2025|Endpoints News|
Researchers behind Replimune’s melanoma study offer a rare protest of FDA’s CRLnews2025-08-04T17:19:03+00:00August 4th, 2025|Endpoints News|
Ignoring China’s biotech industry is no longer an option. It’s a recipe for disasternews2025-07-31T14:00:23+00:00July 31st, 2025|Endpoints News|
